IO Biotech Announces Participation in Upcoming December Investor Conferences
Rhea-AI Summary
IO Biotech (Nasdaq: IOBT) announced participation in two December 2025 investor conferences: the 8th Annual Evercore Healthcare Conference in Coral Gables, Florida on December 2, 2025, and the Piper Sandler 36th Annual Healthcare Conference in New York on December 3, 2025.
Mai-Britt Zocca, PhD, President & CEO, and Amy Sullivan, CFO, will take part in fireside chats and one-on-one investor meetings at both events. Webcasts will be available live and archived under the company’s Investors "News and Events" page for approximately 90 days. Provided webcast links are included for each event.
Positive
- None.
Negative
- None.
News Market Reaction – IOBT
In the Nov 26 session, IOBT gained 0.94%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 26 | Investor conferences | Neutral | +0.9% | Announced December fireside chats and investor meetings with webcast access. |
| Nov 14 | Earnings update | Negative | +1.7% | Q3 loss, going-concern doubt, restructuring, added debt and ATM usage. |
| Nov 12 | Conference participation | Neutral | -6.0% | Planned Jefferies and Piper Sandler investor conference presentations and webcasts. |
| Nov 07 | Preclinical data | Positive | +7.0% | Promising pre-clinical data for IO112 and IO170 and 2026 IND plan for IO112. |
| Oct 20 | Phase 3 results | Positive | +25.2% | Phase 3 Cylembio plus KEYTRUDA data showing improved PFS but missed significance. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows stronger positive reactions to clinical data updates, while earnings and financing disclosures with going-concern language drew more mixed or divergent reactions.
Over the last few months, IO Biotech has combined major clinical updates with financing and restructuring actions. Phase 3 melanoma data reported on Oct 20, 2025 and earlier clinical disclosures were followed by notable positive price moves. By contrast, the Nov 14, 2025 Q3 results highlighted operating losses, going-concern risk, new debt, and workforce reductions. The current conference-participation announcement on Nov 26, 2025 fits a pattern of frequent investor-relations activity following these clinical and financial developments.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Nov. 26, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced the Company’s participation in the 8th Annual Evercore Healthcare Conference taking place in Florida on December 2, 2025, as well as the Piper Sandler Annual Healthcare Conference in New York on December 3, 2025. Mai-Britt Zocca, PhD, President & CEO, and Amy Sullivan, CFO, will participate in a fireside chat and host one-on-one meetings with investors at each conference.
Event: 8th Annual Evercore Healthcare Conference
Location: Coral Gables, Florida
Fireside chat: Tuesday, December 2, 2025, at 7:55 am ET
Participants: Mai-Britt Zocca, PhD, President & CEO, and Amy Sullivan, CFO
Webcast Link: https://wsw.com/webcast/evercore52/iobt/2362844
Event: Piper Sandler 36th Annual Healthcare Conference
Location: New York, New York
Fireside chat: Wednesday, December 3, 2025, at 3:00 pm ET
Participants: Mai-Britt Zocca, PhD, President & CEO, and Amy Sullivan, CFO
Webcast Link: https://event.webcasts.com/starthere.jsp?ei=1742757&tp_key=8b79a34402
Webcasts of the fireside chats may be accessed under “News and Events” in the Investors section of the IO Biotech website at www.iobiotech.com. Archived replays of the webcasts will be available for approximately 90 days following the events.
About IO Biotech
IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines based on its T-win® platform. The T-win platform is based on a novel approach to cancer vaccines designed to activate T cells to target both tumor cells and the immune-suppressive cells in the tumor microenvironment. IO Biotech is advancing its lead cancer vaccine candidate, Cylembio®, in clinical trials, and additional pipeline candidates through preclinical development. IO Biotech is headquartered in Copenhagen, Denmark and has US headquarters in New York, New York.
For further information, please visit www.iobiotech.com. Follow us on our social media channels on LinkedIn and X (@IOBiotech).
Forward-Looking Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including statements regarding the timing or outcome of communications with regulatory authorities including the FDA, the timing or outcome of the submission of regulatory applications, including an IND for IO112, and statements regarding other current or future clinical trials, their timing, progress, enrollment or results, or the company’s financial position or cash runway, are based on IO Biotech’s current assumptions and expectations of future events and trends, which affect or may affect its business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Except to the extent required by law, IO Biotech undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise.
Contact:
Investors and media:
Maryann Cimino, Director of Investor Relations & Corporate Communications
IO Biotech, Inc.
617-710-7305
mci@iobiotech.com
